Immune checkpoint inhibitors for non-small cell lung cancer patients on steroid or non-steroidal anti-inflammatory drugs treatment-therapeutic indication or therapeutic efficacy?
作者信息
Kawase Akikazu
机构信息
First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
出版信息
Transl Cancer Res. 2022 Sep;11(9):3003-3005. doi: 10.21037/tcr-22-2059.
Abstract
摘要
相似文献
1
Immune checkpoint inhibitors for non-small cell lung cancer patients on steroid or non-steroidal anti-inflammatory drugs treatment-therapeutic indication or therapeutic efficacy?接受类固醇或非甾体抗炎药治疗的非小细胞肺癌患者使用免疫检查点抑制剂——治疗指征还是治疗效果？
Transl Cancer Res. 2022 Sep;11(9):3003-3005. doi: 10.21037/tcr-22-2059.
2
Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.既往胸部放疗对晚期非小细胞肺癌免疫检查点抑制剂疗效的影响。
Jpn J Clin Oncol. 2021 Feb 8;51(2):279-286. doi: 10.1093/jjco/hyaa180.
3
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.用于治疗阿尔茨海默病的阿司匹林、甾体类和非甾体类抗炎药。
Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD006378. doi: 10.1002/14651858.CD006378.pub2.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.免疫检查点抑制剂在老年非小细胞肺癌患者中的疗效和安全性。
Jpn J Clin Oncol. 2020 Dec 16;50(12):1447-1453. doi: 10.1093/jjco/hyaa152.
6
[Comparison of efficacy and safety between domestic immune checkpoint inhibitors and pembrolizumab in the treatment of driver gene-negative advanced non-small cell lung cancer].国产免疫检查点抑制剂与帕博利珠单抗治疗驱动基因阴性晚期非小细胞肺癌的疗效及安全性比较
Zhonghua Yi Xue Za Zhi. 2024 Jan 23;104(4):282-289. doi: 10.3760/cma.j.cn112137-20230512-00775.
7
Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.皮质类固醇对免疫检查点抑制剂治疗晚期非小细胞肺癌患者结局的影响。
Eur J Cancer. 2021 Mar;145:245-254. doi: 10.1016/j.ejca.2020.12.012. Epub 2021 Jan 5.
8
[Research progress of immune checkpoint inhibitors in clinical diagnosis and treatment of non-small cell lung cancer].免疫检查点抑制剂在非小细胞肺癌临床诊疗中的研究进展
Zhonghua Zhong Liu Za Zhi. 2020 Sep 23;42(9):713-717. doi: 10.3760/cma.j.cn112152-20200330-00276.
9
Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer.免疫检查点抑制剂单药治疗老年非小细胞肺癌患者的疗效。
Respir Investig. 2023 Sep;61(5):643-650. doi: 10.1016/j.resinv.2023.06.005. Epub 2023 Jul 20.
10
Research advances in immune checkpoint drugs for non-small cell lung cancer.免疫检查点抑制剂治疗非小细胞肺癌的研究进展。
J Drug Target. 2023 Aug;31(7):700-713. doi: 10.1080/1061186X.2023.2235098. Epub 2023 Jul 14.
本文引用的文献
1
Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer.皮质类固醇与非甾体抗炎药联合使用不影响非小细胞肺癌中PD-L1的表达。
Transl Cancer Res. 2022 Sep;11(9):3017-3023. doi: 10.21037/tcr-22-260.
2
PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study.中国晚期非小细胞肺癌（NSCLC）患者的程序性死亡受体配体1（PD-L1）表达：一项多中心回顾性观察研究
J Cancer. 2021 Oct 28;12(24):7390-7398. doi: 10.7150/jca.63003. eCollection 2021.
3
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.非小细胞肺癌患者一线纳武利尤单抗联合伊匹单抗加两个周期化疗（CheckMate 9LA）：一项国际、随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18.
4
Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series.原发性肺鳞状细胞癌的临床特征及程序性死亡受体配体1（PD-L1）表达：病例系列研究
Respir Med Case Rep. 2020 May 31;30:101114. doi: 10.1016/j.rmcr.2020.101114. eCollection 2020.
5
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
6
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.接受基线皮质类固醇治疗以缓解症状和非缓解症状的非小细胞肺癌患者的免疫检查点抑制剂治疗结局。
J Clin Oncol. 2019 Aug 1;37(22):1927-1934. doi: 10.1200/JCO.19.00189. Epub 2019 Jun 17.
7
Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.非小细胞肺癌患者肿瘤细胞和肿瘤浸润免疫细胞 PD-L1 表达的临床病理相关性。
J Immunother. 2019 Jan;42(1):23-28. doi: 10.1097/CJI.0000000000000249.
8
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
9
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.基线类固醇对非小细胞肺癌患者程序性细胞死亡-1 和程序性死亡配体 1 阻断疗效的影响。
J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.
10
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
Zotero 插件